Hata Kenichi, Kato Junichiro, Takahashi Yusuke, Saito Shun, Sakanaka Keigo, Kimura Takahiro
Department of Urology Atsugi City Hospital, 1-16-36, Mizuhiki, Atsugi City, Kanagawa-ken 243-8588, Japan.
Department of Nephrology Atsugi City Hospital, 1-16-36, Mizuhiki, Atsugi City, Kanagawa-ken 243-8588, Japan.
Case Rep Urol. 2024 Aug 12;2024:2760153. doi: 10.1155/2024/2760153. eCollection 2024.
Acquired hemophilia A (AHA) is an acquired bleeding disorder caused by neutralizing antibodies (inhibitors) against Coagulation Factor VIII (FVIII:C), causing sudden hemorrhagic symptoms (i.e., subcutaneous bleeding, intramuscular bleeding, and hematuria). Herein, this study is aimed at presenting a case of AHA diagnosed based on hematuria and reviewing patients who were diagnosed with AHA due to hematuria. A 67-year-old woman was referred to Atsugi City Hospital with painless gross hematuria that began 4 weeks before presentation. Contrast-enhanced computed tomography (eCT) revealed an approximately 2 cm mass in the right renal pelvis, and the patient's activated partial thromboplastin time (APTT) was elevated (61.4 s). The day after the endoscopic biopsy, the patient was in shock due to a large retroperitoneal hematoma. Although her condition stabilized after intravenous radioembolization, she underwent emergency surgeries several times because of rebleeding within the next 3 weeks. At that time, APTT was more prolonged at 106.4 s, and the FVIII:C level was 2%. Mixing tests showed an upwardly convex curve after 2-h incubation, indicating the presence of an inhibitor. Factor VIII inhibitor titer was ≥5.1 Bethesda unit (BU)/mL. A combined product of Plasma-Derived Factors VIIa and X (pd-FVIIa/FX), as second-line hemostatic therapy, as well as cyclophosphamide (CYP), were administered after Recombinant Activated Factor VIIa (rFVIIa) had been ineffective. Following this, the Factor VIII inhibitor titer was undetectable, FVIII:C levels were restored, and APTT decreased to within the normal range. Gross hematuria was significantly alleviated. However, the patient died of cytomegalovirus and fungal infections due to prolonged immunosuppressive therapy. Although AHA diagnosed based on hematuria may have a better prognosis than others, there have been occasional cases with severe outcomes. APTT, detected upon initial hematological testing in patients with hematuria, may be a potential indicator of an existing AHA.
获得性血友病A(AHA)是一种由针对凝血因子VIII(FVIII:C)的中和抗体(抑制剂)引起的获得性出血性疾病,可导致突然出现出血症状(如皮下出血、肌肉内出血和血尿)。在此,本研究旨在介绍一例基于血尿诊断的AHA病例,并回顾因血尿被诊断为AHA的患者。一名67岁女性因无痛性肉眼血尿就诊于厚木市医院,血尿症状在就诊前4周开始出现。增强计算机断层扫描(eCT)显示右肾盂有一个约2厘米的肿块,患者的活化部分凝血活酶时间(APTT)升高(61.4秒)。内镜活检后的第二天,患者因巨大的腹膜后血肿而休克。尽管在静脉内放射性栓塞后病情稳定,但在接下来的3周内,由于再次出血,她接受了多次急诊手术。当时,APTT延长至106.4秒,FVIII:C水平为2%。混合试验显示孵育2小时后曲线向上凸起,表明存在抑制剂。因子VIII抑制剂滴度≥5.1贝塞斯达单位(BU)/毫升。在重组活化因子VIIa(rFVIIa)无效后,给予血浆源性因子VIIa和X的联合产品(pd-FVIIa/FX)作为二线止血治疗,以及环磷酰胺(CYP)。此后,因子VIII抑制剂滴度检测不到,FVIII:C水平恢复,APTT降至正常范围内。肉眼血尿明显缓解。然而,由于长期免疫抑制治疗,患者死于巨细胞病毒和真菌感染。尽管基于血尿诊断的AHA可能比其他类型的预后更好,但偶尔也会出现严重后果的病例。血尿患者初次血液学检测时检测到的APTT可能是现有AHA的潜在指标。